Opyt dlitel'noy terapii patsientov s pishchevodom Barretta
- Authors: Tsukanov V.V1, Onuchina E.V1, Kasparov E.V1, Vasyutin A.V1, Tonkikh Y.L1
-
Affiliations:
- Issue: No 2 (2015)
- Pages: 62-65
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287684
- ID: 287684
Cite item
Abstract
Keywords
Full Text
About the authors
V. V Tsukanov
Email: gastro@impn.ru
E. V Onuchina
Email: alek-a@mail.ru
E. V Kasparov
Email: clinic@impn.ru
A. V Vasyutin
Email: alexander@kraslan.ru
Yu. L Tonkikh
Email: tjulia@bk.ru
References
- Цуканов В.В., Хоменко О.В., Ржавичева О.С., Буторин Н.Н., Штыгашева О.В., Маады А.С., Бичурина Т.Б., Амельчугова О.С. Распространенность H. pylori и ГЭРБ у монголоидов и европеоидов Восточной Сибири. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2009; 3:38-41.
- Буторин Н.Н., Бичурина Т.Б., Цуканов В.В., Каспаров Э.В., Куклин Д.В., Тимошенко В.О., Штыгашева О.В., Маады А.С., Васютин А.В. Распространенность и клинические аспекты пищевода Барретта у населения Восточной Сибири. Терапевт. архив. 2013;1:62-5.
- Rajendra S., Sharma P. Barrett's Esophagus. Curr. Treat. Options. Gastroenterol. 2014;12(2):169-82.
- Maradey-Romero C., Fass R. New and future drug development for gastroesophageal reflux disease. J. Neurogastroenterol. Motil. 2014;20(1):6-16.
- Bennett C., Vakil N., Bergman J. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143(2):336-46.
- Khalaf N., Nguyen T., Ramsey D., El-Serag H.B. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2014;12(11):1832-39.
- Vakil N., van Zanden S.V., Kahrilas P., Dent J., Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 2006; 101(8):1900-20.
- Lundell L.R., Dent J., Bennett J.R., Blum A.L., Armstrong D., Galmiche J.P., Johnson F., Hongo M., Richter J.E., Spechler S.J., Tytgat G.N., Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:2:172-80.
- Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20(5):40-7.
- Ушаева Л.А., Балалыкин Д.А. Хромоэндоскопия в диагностике злокачественных новообразований. Эндоскопическая хирургия. 2008;5:32-3.
- Sharma P., McQuaid K., Dent J., Fennerty M.B., Sampliner R., Spechler S., Cameron A., Corley D., Falk G., Goldblum J., Hunter J., Jankowski J., Lundell L., Reid B., Shaheen N.J., Sonnenberg A., Wang K., Weinstein W.; AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127(1):310-30.
- Агеева Е.С., Штыгашева О.В., Цуканов В.В., Рязанцева Н.В. Иммунологические особенности течения гастродуоденальной патологии у жителей Хакасии. Иммунология. 2009;3:162-65.
- Цуканов В.В., Амельчугова О.С., Буторин Н.Н., Третьякова О.В., Васютин А.В. Современные аспекты эрадикации Helicobacter pylori. Терапевт. архив. 2013;2:73-5.
- Cheng P., Li J.S., Gong J., Zhang L.F., Chen R.Z. Effects of refluxate pH values on duodenogastroesophageal reflux-induced esophageal adenocarcinoma. World J. Gastroenterol. 2011;17(25):3060-065.
- Ojima E., Fujimura T., Oyama K. Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid. Clin. Exp. Med. 2014;18. [Epub ahead of print].
- Matsuzaki J.,Suzuki H., Tsugawa H., Watanabe M., Hossain S., Arai E., Saito Y., Sekine S., Akaike T., Kanai Y., Mukaisho K., Auwerx J., Hibi T. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013;145(6):1300-11.
- Peng S., Huo X., Rezaei D., Zhang Q., Zhang X., Yu C., Asanuma K., Cheng E., Pham T.H., Wang D.H., Chen M., Souza R.F., Spechler S.J. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am. J. Physiol. Gastrointest. 2014;307(2):G129-G139.
- Haidry R.J., Butt M.A., Dunn J.M., Gupta A., Lipman G., Smart H.L., Bhandari P., Smith L., Willert R., Fullarton G., Di Pietro M., Gordon C., Penman I., Barr H., Patel P., Kapoor N., Hoare J., Narayanasamy R., Ang Y., Veitch A., Ragunath K., Novelli M., Lovat L.B.; on behalf of the UK RFA Registry. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut. 2014;24. [Epub ahead of print].
- Singh S., Garg S.K., Singh P.P., Iyer P.G., El-Serag H.B. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8): 1229-37.
- Peura D.A., Wilcox C.M. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus. Postgrad Med. 2014; 126(1):87-96.